BioSpace News Archive

Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission BioCapital BioLabs, a life-science incubator, announced TippingPoint Biosciences and Altay Therapeutics as the winners of the Astellas-sponsored “Future Innovator Prize” at MBC BioLabs.

Lisata Therapeutics, Inc. today announced that a critical milestone has been achieved with the completion of enrollment in the Phase 2b ASCEND study of its novel agent, LSTA1, for the treatment of metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

Humacyte, Inc. today announced that it has submitted a Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible.

Immuneering Corporation (Nasdaq: IMRX) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IMM-6-415, paving the way for the company to initiate a Phase 1/2a clinical trial of this oral, twice-daily small molecule, in development for the treatment of advanced RAF or RAS mutant solid tumors.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced that it has partnered with K2bio to implement novel analysis for cerebrospinal fluid tumor and molecular biomarkers for CNS cancers.

Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, announced its plans to effect.

Bionano Laboratories announced the publication of a study covering the analytical validation of its laboratory developed test, marketed as OGM-Dx™ HemeOne.

Curis, Inc. today announced initial combination study data from its TakeAim Lymphoma trial including 5 primary CNS lymphoma (PCNSL) patients.

Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals.

Shinobi Therapeutics (Shinobi), the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing.